CVRX CVRx Inc

$CVRX My take: a large 3-day presentation/event could have required roughly $350K–$400K in cash. With CVRx needing to preserve cash, they may have used the ATM and sold ~150K–200K shares instead of funding it directly from cash. That could explain the sharp selloff on Sept. 30. Once $2.50 and then $2.00 broke, stop-losses and forced selling likely accelerated the move. The market was already fragile after weeks of negative sentiment, turning the drop into panic selling (-35%). Oct. 1 continued the selloff, but less violently — like aftershocks following an earthquake. Today the market looks a bit calmer. I expect a recovery toward $2 next week. If Chernett files that he increased his stake even 1% — and he could potentially go much higher, possibly toward 10% — that could materially improve sentiment. At $1.55, increasing his position would also significantly lower his average cost. If that happens before the presentation, a move back toward $2.30–$2.50 is possible. Oct. 11

$CVRX I wanted to reshare 's post as well as some screenshots of ChatGPT's partial feedback to it because I think it's important to do our best to stay grounded in verifiable fact as best as we can, while also being accurate in our distinction between speculative explanations and observable fact. Speculating is fine, but I believe it is best to be open and honest about things as best as we can, in my opinion. I have no position here at this time, but I am considering starting one.

$CVRX New data on Barostim presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting highlights real-world safety, reduced hospitalizations, and expanded trial studies. Earlier evidence published from all-payer databases and clinical presentations (such as THT) demonstrated that Barostim is associated with significant reductions in all-cause, cardiovascular, and heart failure hospital visits and emergency department encounters. Real-World Healthcare Use: Earlier evidence published from all-payer databases and clinical presentations (such as THT) demonstrated that Barostim is associated with significant reductions in all-cause, cardiovascular, and heart failure hospital visits and emergency department encounters.

$CVRX i bought at 2.3$ and was sure was a great deal. Still can't believe management is watching this doing nothing. The product is good, let's give it to a company able to execute marketing and commercial!

$CVRX Why Chernett should have sold all at once the entire amount of stocks to just see its price fall so much? is it possible he is going to build a new position at a lower entry price and wanted to send a msg to management? it sounds indeed a bit counterproductive what he did from a pure disposal strategy

$CVRX https://www.sec.gov/edgar/search/#/ciks=0001235912&entityName=CVRx%252C%2520Inc.%2520(CVRX)%2520(CIK%25200001235912) Chernett sold 1,296,750 CVRX shares, reducing his stake from 1,461,750 shares (5.5%) to just 165,000 shares (0.62%), citing "a difference of opinion with management regarding the Company's strategic direction."

$CVRX bears out in full force for an FDA approved product that is bringing in revenue. Can they run the company better? Sure., but those problems are fixable. J&J still owns a steak here. This is not junk. I’m buying.

$CVRX All hopes are pinned on the report to be presented on November 3. No one will take CEO Kevin Heikes at his word—or accept his forecasts and the like—at face value; concrete figures will be required.

$CVRX now would be a great time for the board to buy some shares if they like their plan so much

$CVRX haven't checked my holding on this in a long time. Wtf happened. Thought I was sitting pretty with 8.00 avg.

$CVRX : For all the people talking about being factual, one would think they would mention that the stock continues to sell off, there is no reason or indication that anybody meaningful is increasing their position, and the company has remained completely silent about what is going on since the Pointillist Letter roughly 1 months ago. There's nothing to see here, folks. Shareholders are completely at the mercy of a Managment team that has run this ship so far on the rocks that the hull is torn from bow to stern.

$CVRX Never catch a falling knife. I wanna buy, but I just don’t see the bottom. Guess I’ll have to wait until this thing level out and starts to climb back up… this is ridiculous.

$CVRX wonder how low this trash can go…sub 1 with incompetent bod is not out of the question

$CVRX you would think that this would bounce 10% now that the selling pressure from that large holder is done. Problem is delays in scaling an unproven/inexperienced sales team. Very risky stock at these levels considering the sales headwinds.

$CVRX I want to like thie stock because the valuation seems way too low; but with the performance of the company being this bad... I don't know.

$CVRX when is Chernet gonna buy all shares and kick out mgmt, paving the way to an acquisition?

$CVRX market cap below $40 million for a company that will do $60 Million in revenue this year. Even if you double or triple the share count this is an undervalued disruptive technology.

$CVRX there must be a reason why a big medtech pharma doesn't step in and buy out the co. I mean, any shareholder would now hand their shares at, say, 4$.

$CVRX -- is it possible to sue the officer of a company who obviously did not meet his fiduciary duty, i.e. disposing of an ungodly amount of shares in the middle of a downturn?

$CVRX hikes, now we know who crushed the stock price. It was trading at 2.5$ per share before he started selling. I wonder if it could ever recover to at least that price. But dudes, they need to partner in Europe, they are clearly not able to build a sales force there.